Skip to main content

EFECTO DE DERIVADOS CANNABIONIDES EN EL METABOLISMO LINFOCITARIO: PAPEL EN EL TRASPLANTE ALOGENICO Y LA TERAPIA CON LINFOCITOS T CAR

PI20/01792

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA
Execution centre INSTITUTO DE BIOMEDICINA DE SEVILLA - IBIS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1, the impact of manufacturing procedure on CAR T-cell features

  • Sierro-Martínez, Belén
  • Escamilla Gómez, Virginia|||0000-0002-0639-574X
  • Pérez-Ortega, Laura
  • Guijarro-Albaladejo, Beatriz
  • Hernández-Díaz, Paola
  • de la Rosa-Garrido, Maria
  • Lara-Chica, Maribel
  • Rodríguez Gil, Alfonso|||0000-0003-4430-077X
  • Reguera-Ortega, Juan Luis
  • Sanoja-Flores, Luzalba
  • Arribas-Arribas, Blanca
  • Montiel-Aguilera, M.Á.
  • Carmona, Gloria
  • Robles, Maria Jose
  • Caballero Velazquez, Teresa|||0000-0001-7487-3793
  • Briones Meijide, Javier|||0000-0003-2750-3735
  • Einsele, Hermann
  • Hudecek, Michael
  • Pérez-Simón, José Antonio|||0000-0003-3616-6101
  • García-Guerrero, Estefanía|||0000-0002-3041-9860
Purpose: CAR therapy targeting BCMA is under investigation as treatment for multiple myeloma. However, given the lack of plateau in most studies, pursuing more effective alternatives is imperative. We present the preclinical and clinical validation of a new optimized anti-BCMA CAR (CARTemis-1). In addition, we explored how the manufacturing process could impact CAR-T cell product quality and fitness. Methods: CARTemis-1 optimizations were evaluated at the preclinical level both, in vitro and in vivo. CARTemis-1 generation was validated under GMP conditions, studying the dynamics of the immunophenotype from leukapheresis to final product. Here, we studied the impact of the manufacturing process on CAR-T cells to define optimal cell culture protocol and expansion time to increase product fitness. Results: Two different versions of CARTemis-1 with different spacers were compared. The longer version showed increased cytotoxicity. The incorporation of the safety-gene EGFRt into the CARTemis-1 structure can be used as a monitoring marker. CARTemis-1 showed no inhibition by soluble BCMA and presents potent antitumor effects both in vitro and in vivo. Expansion with IL-2 or IL-7/IL-15 was compared, revealing greater proliferation, less differentiation, and less exhaustion with IL-7/IL-15. Three consecutive batches of CARTemis-1 were produced under GMP guidelines meeting all the required specifications. CARTemis-1 cells manufactured under GMP conditions showed increased memory subpopulations, reduced exhaustion markers and selective antitumor efficacy against MM cell lines and primary myeloma cells. The optimal release time points for obtaining the best fit product were.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells

  • García-Guerrero, Estefanía
  • Rodríguez-Lobato, Luis Gerardo
  • Sierro-Martínez, Belén
  • Danhof, Sophia
  • Bates, Stephan
  • Frenz, Silke
  • Haertle, Larissa
  • Götz, Ralph
  • Sauer, Markus
  • Rasche, Leo
  • Kortüm, K Martin
  • Pérez-Simón, José A.
  • Einsele, Hermann
  • Hudecek, Michael
  • Prommersberger, Sabrina R.
B-cell maturation antigen (BCMA) is the lead antigen for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). A challenge is inter- and intra-patient heterogeneity in BCMA expression on MM cells and BCMA downmodulation under therapeutic pressure. Accordingly, there is a desire to augment and sustain BCMA expression on MM cells in patients that receive BCMA-CAR T-cell therapy. We used all-trans retinoic acid (ATRA) to augment BCMA expression on MM cells and to increase the efficacy of BCMA-CAR T cells in pre-clinical models. We show that ATRA treatment leads to an increase in BCMA transcripts by quantitative reverse transcription polymerase chain reaction and an increase in BCMA protein expression by flow cytometry in MM cell lines and primary MM cells. Analyses with super-resolution microscopy confirmed increased BCMA protein expression and revealed an even distribution of non-clustered BCMA molecules on the MM cell membrane after ATRA treatment. The enhanced BCMA expression on MM cells after ATRA treatment led to enhanced cytolysis, cytokine secretion and proliferation of BCMA-CAR T cells in vitro, and increased efficacy of BCMA-CAR T-cell therapy in a murine xenograft model of MM in vivo (NSG/MM.1S). Combination treatment of MM cells with ATRA and the γ- secretase inhibitor crenigacestat further enhanced BCMA expression and the efficacy of BCMA-CAR T-cell therapy in vitro and in vivo. Taken together, the data show that ATRA treatment leads to enhanced BCMA expression on MM cells and consecutively, enhanced reactivity of BCMA-CAR T cells. The data support the clinical evaluation of ATRA in combination with BCMA-CAR T-cell therapy and potentially, other BCMA-directed immunotherapies., EGG has been supported by Instituto de Salud Carlos III (PFIS - FI12/00189 and PI20/01792). LGRL has been a BITRECS fellow and has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 754550 and from the “La Caixa” Foundation. SD has been supported by the IZKF Würzburg (Interdisziplinäres Zentrum für Klinische Forschung) and is a fellow of the Clinician Scientist Program of the Else-Kröner Forschungskolleg. The authors have been supported by the patient advocacy group 'Hilfe im Kampf gegen den Krebs e.V.', Würzburg, Germany and 'Forschung hilft' - Stiftung zur Förderung der Krebsforschung an der Universität Würzburg. Further, the authors have been supported by the European Union’s Horizon 2020 research and innovation program under grant agreements No 733297 (EURE-CART to MH, HE and SRP) and No 754658 (CARAMBA to MH, SD, SRP and HE), the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG, project number 324392634, TRR 221, subproject A03 to MH and HE), the Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung, BZKF to MH, HE and SRP) and the Stifterverband für die Deutsche Wissenschaft e.V. (to KMK and MH). MS, MH and HE acknowledge funding by the German Ministry for Science and Education (BMBF, Bundesministerium für Bildung und Forschung, grant #13N15986). Further, the authors have been supported by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116026 (T2EVOLVE). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA., Peer reviewed